DMPHF (Dermapharm Holding SE) Total Long-Term Assets: $1,726 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMPHF Dermapharm Holding SE DMPHF
66 GF Score
Price $53.00
! 5 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Total Long-Term Assets?

Dermapharm Holding SE DMPHF 66 Total Long-Term Assets is $1,726 Mil as of Mar. 2026. GuruFocus rates DMPHF with a GF Score™ of 66/100. The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Dermapharm Holding SE's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $1,726 Mil.

Dermapharm Holding SE Total Long-Term Assets Related Terms

Dermapharm Holding SE Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Total Long-Term Assets Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,003.10 931.03 1,668.68 1,556.57 1,737.56

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,601.62 1,698.91 1,729.62 1,737.56 1,725.57
DMPHF
66GF Score
Dermapharm Holding SE DMPHF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $1,726 Mil mean?
Dermapharm Holding SE (DMPHF) has a Total Long-Term Assets of $1,726 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Total Long-Term Assets too high?
Dermapharm Holding SE's current Total Long-Term Assets is $1,726 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Total Long-Term Assets compare to ZTS and UTHR?
Dermapharm Holding SE's Total Long-Term Assets of $1,726 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Total Long-Term Assets is $1,726 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (DMPHF) has a current Total Long-Term Assets of $1,726 Mil. The current Total Long-Term Assets is $1,726 Mil. Dermapharm Holding SE's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Dermapharm Holding SE (DMPHF), the current Total Long-Term Assets is $1,726 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dermapharm Holding SE Business Description

Other Exchanges 0A5J:UKDMPd:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
66GF Score

Get the complete analysis for DMPHF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.00
Price